Nestlé Health Science plots next steps for C. diff drug Vowst after robust uptake
28 Mar 2024
Drug Approval
After a better-than-expected launch, Nestlé Health Science is planning its next commercialization moves for Vowst, an oral pill to treat recurring Clostridioides difficile, or C. diff, infections.
The first-of-its-kind treatment, based on bacterial spores purified from human stool, was approved in April and launched in June. Since then, Vowst has been prescribed by more than 2,000 doctors with more than 3,000 patients now on therapy, said Moreno Perugini, president of active and medical nutrition and pharmaceutical therapies at Nestlé Health Science.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.